Clinical Trials Logo

Pancreatic Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Ductal Adenocarcinoma.

Filter by:

NCT ID: NCT05915351 Recruiting - Pancreas Cancer Clinical Trials

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

NCT ID: NCT05867121 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

NCT ID: NCT05851924 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: May 12, 2023
Phase: Phase 2
Study type: Interventional

The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). The researchers will also look at whether the sequence of the treatment approach (NALIRIFOX + ADXRT and capecitabine followed by surgery, when it is possible) is effective and causes few or mild side effects in participants. An important purpose of the study is to see how the study treatment (NALIRIFOX + AD-XRT and capecitabine) affects participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires

NCT ID: NCT05846516 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)

Start date: March 13, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: - to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) - to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.

NCT ID: NCT05799274 Recruiting - Healthy Volunteers Clinical Trials

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

Start date: November 9, 2023
Phase: Phase 1
Study type: Interventional

The objective of this clinical trial is to determine the safety of an intravenously administered radioisotope, RAD301 ([68Ga]-Trivehexin), in either health volunteers or patients with pancreatic cancer. All subjects will undergo: Screening, which entails physical examination and blood samples for standard blood testing. Subjects that successfully pass screening will undergo: Gallium-68 PET scanning procedures, which will occur during a single day (about 5-6 hours). These subjects will return to the clinic at 2 weeks for additional safety labs. All scanned subjects will also be evaluated by telephone follow up on a weekly basis for 1 month after scanning.

NCT ID: NCT05737615 Recruiting - Pancreatic Cancer Clinical Trials

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr.

NCT ID: NCT05727319 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)

AIR-PANC
Start date: November 17, 2022
Phase:
Study type: Observational

The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients. The main question it aims to answer: Is it feasible to acquire baseline and repeat MR images in Radiotherapy treatment position?

NCT ID: NCT05726864 Recruiting - Colorectal Cancer Clinical Trials

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

AMPLIFY-7P
Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

NCT ID: NCT05708599 Recruiting - Colorectal Cancer Clinical Trials

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

In study, liquid biopsy samples will be obtained from non-small cell lung cancer (NSCLC) including Squamous cell carcinoma, Adenocarcinoma and large cell carcinoma, colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC) patients who undergo treatment according to established standards of care (SoC) at the University Hospital Schleswig-Holstein (UKSH). This study will observe the overall Variant Allele Frequency (VAF) of circulating tumour Desoxyribonucleic acid (ctDNA) levels over the patient therapeutic treatment course and will correlate these findings with tumour response as well as Kirsten rat sarcoma viral oncogene homolog (KRAS)mutation status.

NCT ID: NCT05692596 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Start date: October 6, 2022
Phase:
Study type: Observational

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.